Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Cambridge, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $3.7 billion and a profit of $314 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.8 out of ten, 9 of 9 metrics filed: past 6.9 out of ten, present 7.0 out of ten, future 6.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 7.3 out of ten. +62.4% a year over 10 filed years; profitable in 1 of 10. 72nd percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 4.2 out of ten. Share count grew 3.4% a year. 0% of cash flow returned. Insiders: 279 sales, 0 purchases. 42nd percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 6.8 out of ten. ROE 40%: 40¢ of profit per shareholder dollar. Leverage 84%: owes 84¢ per asset dollar. 68th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 8.4 out of ten. top 16% of 314 in its family; net margin 8.4%. 84th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 5.6 out of ten. top 44% of 315 in its family for leadership; chief executive since 2022. 56th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 6.0 out of ten. top 40% of 272 in its family for room to expand. 60th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 5.9 out of ten. top 41% of 307 in its family for growth drivers. 59th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 7.4 out of ten. top 26% of 234 in its family for expectations against reality. 74th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-12 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-30 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-30 (on EDGAR). Newest filing: Form 4, 2026-10-06. Filings on record since 2002. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Amvuttra 62%, Collaborations 15%, GIVLAARI 8%, OXLUMO 5%, Royalty 5%, ONPATTRO 5%. As tagged in its annual report (Form 10-K, filed 2026-02-12).
Who runs it
Greenstreet, Yvonne (Chief Executive Officer); Bonney, Michael W (Executive Chair); Poulton, Jeffrey V. (EVP, Chief Financial Officer); Mclaughlin, Melissa (Chief Human Resources Officer); Garg, Pushkal (EVP Chief R&D); Tanguler, Tolga (EVP, Chief Commercial Officer); Supran, Bryan (EVP, CLO and Secretary); Fitzgerald, Kevin Joseph (CSO & EVP, Head of Research); Cravatt, Benjamin (director); Pyott, David E I (director); and 8 more. 18 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-06.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.